Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab)
Rituximab is a chemeric murine/human anti-B lymphocyte antigen CD20 monoclonal antibody used in the treatment of rheumatoid arthritis resistant to treatment by one or more anti TNF-alpha therapies (1). The recommended dose for an efficient depletion of the B CD 20 lymphocytes in rheumatoid arthritis...
Main Authors: | V. Bruzzese, J. Pepe |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2011-06-01
|
Series: | Reumatismo |
Online Access: | http://www.reumatismo.org/index.php/reuma/article/view/454 |
Similar Items
-
Application of monoclonal anti-CD20 antibody rituximab in the treatment of non-Hodgkin's lymphoma
by: Mihaljević Biljana, et al.
Published: (2008-01-01) -
Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.
by: Sigrid Lunde, et al.
Published: (2016-01-01) -
Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
by: Stefan Gingele, et al.
Published: (2018-12-01) -
B cell populations in the myasthenia thymus that bind Rituximab (anti-CD20)
by: Zainudeen, Z, et al.
Published: (2014) -
Surface levels of CD20 determine anti-CD20 antibodies mediated cell death in vitro.
by: Vijay Singh, et al.
Published: (2014-01-01)